Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul;86(1):21-8.
doi: 10.1111/cge.12392. Epub 2014 May 9.

The emerging era of pharmacogenomics: current successes, future potential, and challenges

J W Lee  1 , F Aminkeng, A P Bhavsar, K Shaw, B C Carleton, M R Hayden, C J D Ross
Affiliations
Review

The emerging era of pharmacogenomics: current successes, future potential, and challenges

J W Lee et al. Clin Genet. 2014 Jul.

Abstract

The vast range of genetic diversity contributes to a wonderful array of human traits and characteristics. Unfortunately, a consequence of this genetic diversity is large variability in drug response between people, meaning that no single medication is safe and effective in everyone. The debilitating and sometimes deadly consequences of adverse drug reactions (ADRs) are a major and unmet problem of modern medicine. Pharmacogenomics can uncover associations between genetic variation and drug safety and has the potential to predict ADRs in individual patients. Here we review pharmacogenomic successes leading to changes in clinical practice, as well as clinical areas probably to be impacted by pharmacogenomics in the near future. We also discuss some of the challenges, and potential solutions, that remain for the implementation of pharmacogenomic testing into clinical practice for the significant improvement of drug safety.

Keywords: ADRs; adverse drug reactions; anthracycline; carbamazepine; cisplatin; codeine; pharmacogenomics; warfarin.

PubMed Disclaimer

References

    1. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8(4):283–289. - PubMed
    1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205. - PubMed
    1. Severino G, Del Zompo M. Adverse drug reactions: role of pharmacogenomics. Pharmacol Res. 2004;49(4):363–373. - PubMed
    1. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4:S73–S77. - PMC - PubMed
    1. Volpe D, McMahon Tobin G, Mellon R, et al. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011;59(3):385–390. - PubMed

Publication types